Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep-Dec:23:S103-S110.
doi: 10.1016/j.vacun.2022.05.005. Epub 2022 Jul 7.

Third booster vaccination and stopping the Omicron, a new variant of concern

Kiarash Ghazvini  1   2 , Mohsen Karbalaei  3 , Masoud Keikha  1   2
Affiliations
Review

Third booster vaccination and stopping the Omicron, a new variant of concern

Kiarash Ghazvini et al. Vacunas. 2022 Sep-Dec.

Abstract
in English, Spanish

The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; however, recent studies declare that the third booster vaccination can elicit higher antibodies concentration as well as cross-reaction between neutralizing antibodies and new SARS-CoV-2 variants. On the other hand, although a third booster vaccination seems to be benefit in some immunocompromised patients such as recipients of solid-organ transplants or hemodialysis patients, but in other immunosuppressed patients, for instance patients with B cell lymphoproliferative disease partially respond to SARS-CoV-2. Herein, we evaluate the effectiveness of the third booster vaccination against Omicron variant using comprehensive literature review.

La variante ómicron de SARS-CoV-2 es un miembro reciente de variantes preocupantes, que confiere anticuerpos neutralizantes y escapa al sistema inmune debido a que alberga más de 40 mutaciones. Las evidencias actuales sugieren que dos dosis de la vacuna contra la SARS-CoV-2 no protegen eficientemente frente a las nuevas variantes de SARS-CoV-2. Sin embargo, los estudios recientes afirman que la tercera vacuna de refuerzo puede suscitar una mayor concentración de anticuerpos, así como una reacción cruzada entre los anticuerpos neutralizantes y las nuevas variantes de SARS-CoV-2. Por otro lado, aunque la tercera vacuna de refuerzo parece ser beneficiosa para algunos pacientes inmunocomprometidos, tales como los receptores de trasplantes de órganos sólidos, o los pacientes de hemodiálisis, otros pacientes inmunosuprimidos, como por ejemplo los pacientes con enfermedad linfoproliferativa de células B, responden parcialmente a la SARS-CoV-2. Por tanto, evaluamos la efectividad de la tercera vacuna de refuerzo frente a la variante ómicron, utilizando una revisión amplia de la literatura.

Keywords: COVID-19; Omicron; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
the rising trend of the VOC omicron (B.1.1.529) throughout the worldwide, available at: https://www.gisaid.org/hcov19-variants/.
Fig. 2
Fig. 2
the global status vaccine coverage against the SARS-CoV-2 infection, available at: www.cbrc.kaust.edu.sa/covmt/.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sachs J.D., Karim S.A., Aknin L., Allen J., Brosbøl K., Barron G.C., et al. Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. Lancet. 2020;396(10257):1102–1124. - PMC - PubMed
    1. Ghazvini K., Karbalaei M., Keikha M. What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies. Le Pharmacien Hospitalier & Clinicien. 2021;56(2):217.
    1. Keikha M., Karbalaei M. Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study. New Microbes New Infect. 2021;42 - PMC - PubMed
    1. Yousefi B., Valizadeh S., Ghaffari H., Vahedi A., Karbalaei M., Eslami M. A global treatments for coronaviruses including COVID-19. J Cell Physiol. 2020;235(12):9133–9142. - PMC - PubMed
    1. Mansury D., Moghim S. Coronavirus disease 2019 (COVID-19): a new pandemic and its challenges. J Curr Biomed Rep. 2020;1(2):52–57.

LinkOut - more resources